Information about the use and accuracy of breast cancer tests is lacking, study finds

	Tweet

A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin). Published in the November 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the review suggests that many breast cancer patients who may benefit from trastuzumab are not receiving it, and that some women receiving the drug have never been tested for the receptor it targets.

Standard care now dictates that women with early-stage breast cancer should be tested to see if they have tumors that express the HER2 protein. Those who test positive are candidates for treatment with trastuzumab, which is only effective in HER2-positive cancers.

Researchers at the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) and led by Kathryn A. Phillips, PhD, of the University of California-San Francisco, reviewed the medical literature to determine how HER2 testing is being used in routine clinical practice. 

The studies they found reported that up to two-thirds of patients eligible for HER2 testing had no documentation of a test in their health insurance records. About one in five women who received trastuzumab had no documentation of a positive HER2 test in their health insurance records. The studies also revealed that about one in five HER2 test results may be incorrect.

The authors also found that studies looking at the economic issues associated with prescribing trastuzumab often did not explicitly consider the role of HER2 testing, which can have a substantial impact on the cost-effectiveness of the therapy.

Given the increasing use of targeted therapies like trastuzumab, proper testing will become more important to ensure that medications are directed only to the patients who will benefit from them.

“Our review of the literature suggests that there are important knowledge gaps regarding the real-world use of HER2 testing and trastuzumab,” said Dr. Elena Elkin, a researcher at Memorial Sloan-Kettering Cancer Center in New York and one of the study’s authors. “Filling these gaps may help optimize limited health care resources and improve care for women with breast cancer,” she added.

###

Article: “Clinical practice patterns and cost-effectiveness of HER2 testing strategies in breast cancer patients.” Kathryn A. Phillips, Deborah A. Marshall, Jennifer S. Haas, Elena B. Elkin, Su-Ying Liang, Michael J. Hassett, Ilia Ferrusi, Jane E. Brock, and Stephanie L Van Bebber. Cancer; Published Online: September 14, 2009 (DOI: 10.1002/cncr.24574); Print Issue Date: November 15, 2009.

Contact: David Sampson

American Cancer Society

RELATED STORIES:
New Insight into the Biology of the BRCA1 Breast Cancer Gene   Cell of Origin Identified for Common Type of Breast Cancer   Study identifies women with breast cancer most likely to benefit from aromatase inhibitor   New scans prompt mastectomies for breast patients   Metabolic syndrome linked to breast cancer   New national poll: 89 percent of women said mammograms vital to their health   Breast cancer subtypes linked to survival from secondary brain tumors   Ethnic gaps in breast cancer linked to hormones   ‘Pink ribbon dollars’ help fill financial gaps for breast cancer programs   Improving understanding of cell behaviour in breast cancer   Mother-Daughter Breast Density Study Points Way to Earlier Cancer Risk Assessment   Breast cancer pain more severe in non-whites   Women with BRCA Mutation, Or High Degree of Worry, Most Likely to Undergo Prophylactic Mastectomy   ‘Hidden’ Cancer Cells Not a Factor in Early-Stage Breast Cancer Survival Rates   Could therapeutic vaccines treat hard to beat breast cancers?   What Should a Teenage Girl Do if She Finds a Lump in her Breast?   Overeating plus inactivity ups breast cancer risk   UK breast screening information has serious shortcomings   Weekly Taxol best for followup breast cancer care   UB played major role in study on drug that reduces breast cancer in high-risk women   Significant Advance in Treatment of Breast Cancer Reported   Obese Women Have Higher Risk Of Suffering Breast Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]